The use of the CDK4/6 inhibitors palbociclib [186], ribociclib [187], and abemaciclib [188] as first- or second-line therapy confers survival benefits for patients with HR-positive/HER2-negative advanced breast cancer. Here, CDK4 is linked to breast cancer.